30-Mar-2026
MIMEDX Announces Launch of CHORIOFIX
Globe Newswire (Mon, 23-Mar 8:00 AM ET)
MIMEDX Expands Surgical Product Portfolio with the Launch of AMNIOFIX Thyroid Shields
Globe Newswire (Thu, 5-Mar 8:00 AM ET)
MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
Globe Newswire (Wed, 25-Feb 4:08 PM ET)
Globe Newswire (Tue, 17-Feb 8:00 AM ET)
Globe Newswire (Wed, 4-Feb 10:27 AM ET)
MIMEDX Celebrates 15 Year Anniversary of EPIFIX and AMNIOFIX
Globe Newswire (Mon, 2-Feb 8:00 AM ET)
MIMEDX Sees Opportunity as CMS Finalizes 2026 Medicare Reimbursement Reform
Market Chameleon (Mon, 3-Nov 4:41 AM ET)
MIMEDX Delivers Record-Breaking Q3 Revenue with Strong Margins and Upbeat 2025 Outlook
Market Chameleon (Thu, 30-Oct 6:43 AM ET)
Market Chameleon (Thu, 30-Oct 4:08 AM ET)
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Mimedx Group trades on the NASDAQ stock market under the symbol MDXG.
As of March 30, 2026, MDXG stock price climbed to $3.86 with 869,179 million shares trading.
MDXG has a beta of 0.71, meaning it tends to be less sensitive to market movements. MDXG has a correlation of 0.11 to the broad based SPY ETF.
MDXG has a market cap of $571.12 million. This is considered a Small Cap stock.
Last quarter Mimedx Group reported $118 million in Revenue and $.14 earnings per share. This beat revenue expectation by $13 million and exceeded earnings estimates by $.04.
In the last 3 years, MDXG traded as high as $10.14 and as low as $3.08.
The top ETF exchange traded funds that MDXG belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.
MDXG has underperformed the market in the last year with a price return of -50.1% while the SPY ETF gained +12.7%. MDXG has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -44.1% and -11.9%, respectively, while the SPY returned -8.2% and -4.3%, respectively.
MDXG support price is $3.71 and resistance is $3.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDXG shares will trade within this expected range on the day.